• Daria Mochly-Rosen, PhD
    Daria Mochly-Rosen, PhDFounder, SAB Chair

    Daria Mochly-Rosen, Professor of Chemical and Systems Biology, is the George D. Smith Professor for Translational Medicine and the co-director of SPARK at Stanford. Daria leads a multi-disciplinary research lab that includes chemists, biochemists, biologists and physician scientists and has used her basic research discoveries to develop a number of drug leads for human diseases with a particular interest in mitochondrial biology and pathology. The reseach in her lab led to the identification of a novel inhibitor of pathological mitochondrial fission, and its use in a variety of chronic diseases, including neurodegeneration. This technology provided the basis for Mitoconix, which she founded in FutuRx in 2016.

    She was the chair of her department (2001-2004) and Senior Associate Dean for Research (2013-2016), has published over 250 papers, over 30 patents and founded two other companies: KAI Pharmaceuticals (2003-2011, the maker of Parsabiv for kidney dialysis patients; aquiered by Amgen and sold by Amgen and Ono since 2016), ALDEA/Aviv (2013; now licensed to Foresee).

    Daria is also the founder, president and co-director of SPARK At Stanford (since 2006), which provides education in drug discovery and development and has helped over 100 inventors (60% of the participants) of biopharmaceuticals and diagnostics bring their invention to clinical studies and/or to licensing. She is the president founder of SPARKGlobal, which help establish SPARK programs in >50 academic institutions around the world, increasing the likelihood that new treatments will be developed from academic research efforts across the globe.

    Dr. Mochly-Rosen holds a Ph.D. in Chemical Immunology from the Weizmann Institute of Science in Israel, and completed her postdoctoral training at University of California, Berkeley.

    • Orian Shirihai
      Orian Shirihai

      Orian Shirihai MD PhD received his PhD from the Technion, Haifa, Israel. He did his post-doctoral fellowship at Harvard Medical School. He is currently a Professor of Medicine at the University of California Los Angeles (UCLA) where he heads UCLA Metabolism Center (Metabolism Theme) and UCLA Mitochondria Core. Before that he was an associate professor and the head of a research group at Boston University in Boston, Massachusetts, where he founded the first of its kind Academic Bioenergetics Core that worked with industry partners. Dr. Shirihai is an expert in mitochondrial dynamics and bioenergetics and has published extensively in the fields of diabetes and obesity. His group has developed numerous new methods for the quantification of mitochondrial dynamics and bioenergetics parameters. Dr. Shirihai has lead educational initiatives in the field of mitochondrial biology in the US, Brazil, Chile, England, Sweden and Israel. His laboratory collaborates with groups at the Weizmann Inst., Ben Gurion University and Bar Ilan University in Israel. He has co-founded Bioenergetics-CRO in Boston and EnspireBio in Los Angeles. He has collaborated and consulted for various pharma and biotech companies in the US, France, Sweden and Israel.